Skip to content
JustPartnering
Biotech business development & licensing advisory

Find the right partners. Close the right deals.

JustPartnering helps biotech and research teams identify, position, and license their assets to the right pharma and biotech partners.

We find who is actively in-licensing in your space, prepare the materials they need to see, and keep every conversation moving until terms are agreed.

We become your BD function, without the overhead of hiring one.

A biotech BD consultant helps life sciences companies identify potential licensing partners, develop pitch materials, manage outreach, and negotiate deal terms. JustPartnering provides end-to-end business development and licensing support for biotech and research teams, from target list to signed agreement. Our hourly model has no retainer, success fee, or minimum commitment, so our advice stays focused on getting you the right deal.

Not sure which partners to approach first?

A target list shows who is actively in-licensing in your space and the named contact at each one.

Biocontacts

Every target list we build starts in Biocontacts.

Biocontacts is JustPartnering’s partnering database. Since 2007 we have recorded which life science companies in-license, what each one wants to bring in, and who handles it. Your outreach goes to companies with a stated interest in assets like yours, through a named contact.

What they want to in-license
Therapeutic areas, modalities, and indications.
Stages they will look at
The development stages each company considers.
Notes from our meetings
Interests refreshed from our own meetings: 300+ face-to-face a year, and many more held virtually.
Who handles it
The BD, external innovation, and search and evaluation contacts, re-checked as people move.
Example profile, anonymised

Mid-size oncology developer

  • Oncology
  • ADC
  • Solid tumours
  • Preclinical to Phase 1

Looking to in-license

Preclinical to early clinical ADC assets in solid tumours, from Asia-Pacific and European originators.

Last confirmed at a partnering meeting

Head of Search & Evaluation

BD contact

Fit for a preclinical ADC in solid tumours

  • Wants ADCs
  • Focused on solid tumours
  • Takes preclinical assets
Companies that in-license
2,500+
Pharma, biotech, medical device, and animal health.
BD contacts mapped
4,000+
The people whose job is to review assets like yours.
Partnering keywords
1,000+
Mapped to what each company wants.
Updates
Weekly
Built through partnering work since 2007.
How we can help

How we get your asset in front of the right partners

From positioning through to signed deal, we support every stage of the partnering process.

01
Target identification

Identify the right partners

Receive a prioritised target list of in-licensing companies, filtered to fit your asset.

  • Includes contact names, job titles, and email addresses, ready to action
  • Ranked strong, good, or possible, so you know who to approach first
  • Delivered as a working document for independent use, or with our support

Most curated target lists cost US$700–$2,000, ready within 3 days

Contains a ranked list of companies in-licensing assets in your therapeutic area or disease indication and at your stage of development.

Get a target list
02
Pitch development

Build a partner-ready pitch

A pitch built for in-licensing teams: TPP-aligned and competitively positioned.

  • Positioned against the competitive landscape, not just describing the science
  • Structured around what pharma and biotech in-licensing teams look for
  • Suitable for partnering conferences, investor meetings, and email outreach
03
Outreach & introductions

Run targeted outreach and secure meetings

We reach out to the right-fit companies on your behalf, or hand you the list to run yourself.

  • Relevant in-licensing contacts selected by role and in-licensing activity
  • All correspondence copied into a shared folder so you have full visibility
  • Follow-up rounds managed for you, because that is where most outreach stalls
04
Conference support

Partnering conferences, run for you

We attend 4+ major conferences a year, including BIO and BIO-Europe, and handle meetings on your behalf.

  • Active representation: we secure one-on-one meetings for your asset
  • Passive option: we upload your profile and report on inbound interest
  • Conference and travel costs shared across clients to keep costs low
05
Deal management

End-to-end negotiation and deal close

We coordinate term sheets, diligence, and contracting, keeping both sides moving toward close.

  • Term sheet, diligence, and contract workstreams tracked in one place
  • Data room setup and management handled if needed
  • Hand off as much or as little as you need
Most outreach stalls during follow-up, not the first email. We manage every round to keep it moving.
How we compare

How we work versus going it alone

What running a partnering process with internal resource costs you, versus engaging JustPartnering.

FactorOn your ownWith JustPartnering
Cost modelNo upfront cost, but significant internal time diverted from R&D.Hourly. No retainer, no success fees, no minimum commitment.
TimelineNo defined process: momentum depends on whoever has spare capacity that week.Every viable partner approached in parallel, with follow-up on a schedule that doesn’t depend on who has time that week.
Track record

Built on partnering work since 2007.

50+
Assets progressed from lab to clinic
19+
Years of partnering experience

Common questions

What is Biocontacts?
Biocontacts is JustPartnering’s partnering database. It records 2,500+ life science companies that in-license, what each one wants to bring in by therapeutic area, modality, and stage, and 4,000+ business development contacts. We have built it through partnering work since 2007, and every BD engagement starts from it.
When is the right time to start a partnering process?
Ideally 18 to 24 months before you need a signed deal, so your target list, materials, and outreach can run across more than one partnering conference cycle. Starting when runway is already short weakens your negotiating position.
What do pharma companies look for when in-licensing?
In-licensing teams evaluate assets on scientific differentiation, clinical and regulatory feasibility, commercial potential, and team credibility. They want to see a clear target product profile, a realistic development plan, an honest competitive landscape, and evidence that the team understands what it takes to get to market.
How long does a biotech licensing deal take to close?
There's no fixed timeline. Some deals close in months, others take years, depending on asset stage, therapeutic area, and partner responsiveness. What we do promise: every viable partner gets approached, every follow-up gets managed.
What materials do I need for a biotech partnering process?
At minimum you need a pitch deck, a one-page asset summary, and a data room with your key scientific and regulatory documents. Your pitch deck should cover the unmet need, your asset’s mechanism and differentiation, the target product profile, development status, regulatory pathway, and partnering ask.
How do biotech licensing deals work?
A biotech licensing deal typically involves one company granting another the rights to develop and commercialise an asset in exchange for upfront payments, development milestones, and royalties on future sales. Deal structures vary widely depending on asset stage, therapeutic area, territory, and the relative leverage of each party.
Related: our biotech out-licensing advisory and APAC biotech partnering approach. Want to see the first deliverable before committing to more? Get a target list. Preparing for a conversation? The free Pitch Deck Toolkit has templates and guides to help you get ready.

Ready to move your asset forward?

Talk to a senior advisor about your asset and what partnering could look like. No brief required. Tell us where you’re stuck.

Let’s talk